Peter Nash, MD

Peter Nash, MD
 

Professor of Department of Medicine
Director of Rheumatology Unit on the Sunshine Coast
University of Queensland
Queensland, Australia

What are treatment triggers for employing disease-modifying anti-rheumatic drugs (DMARDs)? What classes of biologic agents -- including IL-6 inhibitors -- have demonstrated efficacy as monotherapy? Video

What are treatment triggers for employing disease-modifying anti-rheumatic drugs (DMARDs)? What classes of biologic agents -- including IL-6 inhibitors -- have demonstrated efficacy as monotherapy?

What are accepted treatment triggers for employing disease-modifying anti-rheumatic drugs (DMARDs)? And what classes of biologic agents — including IL-6 inhibitors and others — have demonstrated efficacy as monotherapy?
Peter Nash, MD

Peter Nash, MD

What is the immunopathobiologic mechanism of action for agents targeting IL-6 in RA? Are these MoAs synergistic with other MoAs? With which other agents should IL-6 targeting agents be used? Video

What is the immunopathobiologic mechanism of action for agents targeting IL-6 in RA? Are these MoAs synergistic with other MoAs? With which other agents should IL-6 targeting agents be used?

What is the precise immunopathobiologic mechanism of action for agents targeting IL-6 in the setting of RA? Are these MoAs synergistic with other MoAs? If so with which other agents should IL-6 targeting agents be used?
Peter Nash, MD

Peter Nash, MD

What are the strategies for individualizing treatment in patients with RA? Video

What are the strategies for individualizing treatment in patients with RA?

What are the strategies for individualizing treatment in patients with RA?
Peter Nash, MD

Peter Nash, MD

How long of a trial using traditional DMARD therapy with methotrexate do you recommend prior to intensifying treatment with a biologic agent? Video

How long of a trial using traditional DMARD therapy with methotrexate do you recommend prior to intensifying treatment with a biologic agent?

How long of a trial using traditional DMARD therapy with methotrexate do you recommend prior to intensifying treatment with a biologic agent?
Peter Nash, MD

Peter Nash, MD

Among the biologic agents, are there any significant efficacy or safety differentiators that prompt you to deploy one agent in preference to another, in any particular sequence? Video

Among the biologic agents, are there any significant efficacy or safety differentiators that prompt you to deploy one agent in preference to another, in any particular sequence?

Among the biologic agents, are there any significant efficacy or safety differentiators that prompt you to deploy one agent in preference to another, in any particular sequence?
Peter Nash, MD

Peter Nash, MD

When a suboptimal clinical response has been encountered with TNF, do you recommend switching to a biologic with a different MoA, such as an IL-6 inhibitor or co-modulating agent? Video

When a suboptimal clinical response has been encountered with TNF, do you recommend switching to a biologic with a different MoA, such as an IL-6 inhibitor or co-modulating agent?

When a suboptimal clinical response has been encountered with TNF, do you recommend switching to a biologic with a different MoA, such as an IL-6 inhibitor or co-modulating agent?
Peter Nash, MD

Peter Nash, MD

When a suboptimal clinical response has been encountered with a traditional DMARD, what therapeutic approaches for escalating therapy are appropriate? Video

When a suboptimal clinical response has been encountered with a traditional DMARD, what therapeutic approaches for escalating therapy are appropriate?

When a suboptimal clinical response has been encountered with a traditional DMARD, what therapeutic approaches for escalating therapy are appropriate?
Peter Nash, MD

Peter Nash, MD

What is your assessment of the cardiovascular risk profile associated with IL-6 therapy? And the possible role of IL-6 inhibition as a mitigator of any effects related to LDL elevation? Video

What is your assessment of the cardiovascular risk profile associated with IL-6 therapy? And the possible role of IL-6 inhibition as a mitigator of any effects related to LDL elevation?

What is your assessment of the cardiovascular risk profile associated with IL-6 therapy? And the possible role of IL-6 inhibition as a mitigator of any effects related to LDL elevation?
Peter Nash, MD

Peter Nash, MD

What metabolic or hematologic markers should we monitor in patients on IL-6 therapy? Video

What metabolic or hematologic markers should we monitor in patients on IL-6 therapy?

What metabolic or hematologic markers should we monitor in patients on IL-6 therapy?
Peter Nash, MD

Peter Nash, MD

What are the risks for infection when treating RA patients with biologics? Video

What are the risks for infection when treating RA patients with biologics?

What are the risks for infection when treating RA patients with biologics?
Peter Nash, MD

Peter Nash, MD